Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · July 19, 2022

Consolidation With Reduced-Dose WBRT for Patients With Primary CNS Lymphoma

Blood Advances

 

Additional Info

Disclosure statements are available on the authors' profiles:

Blood Advances
Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: a LOC-network study
Blood Adv 2022 Jun 30;[EPub Ahead of Print], P Lesueur, G Damaj, K Hoang-Xuan, V Roland, A Schmitt, O Chinot, M Fabbro, P Agape, C Moluçon Chabrot, S Chebrek, A Alentorn, L Feuvret, D Delgadillo, D Stefan, S Choquet, L Nichelli, K Mokhtari, B Mathon, S Dureau, C Soussain, C Houillier

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading